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BACKGROUND: Guidelines recommend tight control of hemoglobin
A1c (HbA1c), low-density lipoprotein cholesterol (LDL-C), and blood
pressure (BP) for patients with diabetes. The degree to which these in-
termediate outcomes are simultaneously controlled has not been ex-
tensively described.
OBJECTIVE: Describe the degree of simultaneous control of HbA1c,
LDL-C, and BP among Veterans Affairs (VA) diabetes patients defined
by both VA and American Diabetes Association (ADA) guidelines.
DESIGN: Cross-sectional cohort.
PATIENTS: Eighty-thousand two hundred and seven VA diabetes pa-
tients receiving care between October 1999 and September 2000.
MEASURMENTS: We defined simultaneous control of outcomes using
1997 VA Guidelines (in place in 2000) (HbA1co9.0%; LDL-Co130 mg/
dL; systolic BPo140 mmHg; and diastolic BPo90 mmHg) and
2004 ADA guidelines (HbA1co7.0%; LDL-Co100 mg/dL; systolic
BPo130 mmHg; and diastolic BPo80 mmHg). A patient is considered
to have simultaneous control of the intermediate outcomes for a given
definition if the average of measurements for each outcome was below
the defined threshold during the study period.
RESULTS: Using VA guidelines, 31% of patients had simultaneous
control. Control levels of individual outcomes were: HbA1c (82%),
LDL-C (77%), and BP (48%). Using ADA guidelines, 4% had simulta-
neous control. Control levels of individual outcomes were: HbA1c
(36%), LDL-C (41%), and BP (23%). Associations between individual
risk factors were weak. There was a modest association between LDL-C
control and control of HbA1c (odds ratio [OR] 1.51; 95% confidence in-
terval [CI] 1.44, 1.58). The association between LDL-C and BP control
was clinically small (1.26; 1.21, 1.31), and there was an extremely
small association between BP and HbA1c control (0.95; 0.92, 0.99).
Logistic regression modeling indicates greater body mass index, African
American or Hispanic race-ethnicity, and female gender were negatively
associated with simultaneous control.
CONCLUSION: While the proportion of patients who achieved minimal
levels of control of HbA1c and LDL-C was high, these data indicate a low
level of simultaneous control of HbA1c, LDL-C, and BP among patients
with diabetes.
KEY WORDS: blood pressure; diabetes mellitus; hemoglobin A-glyco-
sylated; lipoproteins-LDL cholesterol; United States Department of Vet-
erans Affairs.
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A s individual risk factors, control of blood glucose,
1–3 low-
density lipoprotein cholesterol (LDL-C),4 and blood pres-
sure (BP)5,6 are associated with reduced risk of complications
among patients with diabetes. However, most studies7–22 have
concentrated on control of individual intermediate outcomes
(i.e., vascular risk factors). A few studies reported on the
number of categories of diabetes control achieved by individ-
ual patients.8,19,21 However, as complex and expensive inter-
ventions are developed to control multiple cardiovascular risk
factors in patients with diabetes,23,24 it becomes important to
understand the degree to which control of these risk factors
may or may not be interrelated.
The present study: describes the extent of simultaneous
control of hemoglobin A1c (HbA1c), LDL-C, and BP, measures
the association among intermediate outcomes, and identifies
patient characteristics associated with simultaneous control
of these outcomes among primary care patients with diabetes.
METHODS
For eligible patients who received care from the Veterans Af-
fairs (VA) health care system in Fiscal Year (FY) 1999, we ex-
tracted data on HbA1c, LDL-C, and BP (systolic [SBP] and
diastolic [DBP]) for FY2000 (October 1, 1999 to September 30,
2000). The study was approved by the Institutional Review
Board of the Durham, NC, VA Medical Center.
Data Sources
Veterans Health Administration (VHA) Diabetes Registry and
Dataset. The VHA Diabetes Registry and Dataset was used to
obtain outcomes data and establish the diabetes cohort. The
Registry contains 3 files. The Pharmacy File has medication
data for patients who have filled an outpatient prescription for
insulin, oral hypoglycemic agents, or blood glucose monitoring
supplies at any VA. The Laboratory File contains data on tests
directly related to diabetes (including HbA1c and LDL-C). The
Vitals File has information on patient height, weight, body
mass index (BMI), BP, and receipt of influenza and pneumo-
nia vaccines.25
Information is transmitted to the Registry via yearly down-
loads of diabetes-related data from individual VA-facility com-
puter systems. Pharmacy file data are included on patients
with a filled outpatient prescription for insulin, oral hypo-
glycemic agents, or glucose monitoring supplies. Laboratory
and vitals data are included for patients who have 1 VA in-
patient admission and/or 2 VA outpatient encounters with
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an associated International Classification of Disease 9-Clinical
Modifications (ICD-9-CM) diagnosis code for diabetes.26
Specific variables captured by the Registry include: HbA1c,
LDL-C, BP, BMI, and pharmaceutical treatment.
VHA Corporate Databases. Multiple VHA databases housed at
the Austin Automation Center were used to obtain data on pa-
tient demographics, health care utilization, comorbidities, and
vital status.27 Patients’ vital status is recorded in the Benefici-
ary Identification and Record Locator System (BIRLS).28 En-
counter and demographic data were obtained from the VA
Medical SAS Datasets.27 Specific ICD-9-CM codes used to iden-
tify patients with diabetes were obtained from the 2003 version
of the Agency for Healthcare Research and Quality Clinical
Classification Software.29 The Johns Hopkins Adjusted Clinical
Groups (ACGs)/Aggregated Diagnostic Groups files contain in-
formation on patient comorbidities used for risk adjustment.30
Subjects—Diabetes Cohort
We used the VHA Diabetes Registry, Medical SAS Datasets,
and BIRLS to construct a national cohort of diabetes patients
who received VA primary care services. Patients identified as
having diabetes had to meet both pharmacy and utilization
criteria.
During FY1999, 503,371 patients were in the VHA Dia-
betes Registry.26 We identified 224,221 patients who met all
the following inclusion criteria during FY1999: (1) were alive
on October 1, 1999 (using BIRLS and Medical SAS Datasets);
(2)2 nonmental health outpatient visits with an associated
diabetes diagnosis, and/or 1 nonmental health inpatient
discharge with an associated diagnosis of diabetes (using Med-
ical SAS Datasets); (3) filled 1 prescription for insulin, oral
hypoglycemic agents, or blood glucose monitoring supplies
(using Diabetes Registry); and (4) had 1 outpatient visit to
a VA primary care clinic (using Medical SAS Datasets).
Individuals were considered primary care patients of the
VA facility where they made the greatest number of primary
care visits during 1999. In case of a tie, the patient was ran-
domly assigned to 1 of the tied locations. Once patients’ pri-
mary care clinics were determined, a random sample of 800
diabetes patients meeting the above criteria was drawn from
each VA facility operating in 1999.31 If a location did not have
800 eligible patients, all eligible patients were retained.
Subjects—Study Exclusion Criteria
Patients were excluded from this study if they met any of the
following criteria: (1) did not have a record for each intermedi-
ate outcome in 2000 and a BMI measurement (excluded so
that all analyses include the same patients); (2) age o18 years;
(3) had a VA endocrinology visit during 1999 to 2000 (because
determinants of control may be different for patients enrolled
in specialty clinics32); (4) had no VA primary care visit in 2000;
(5) died during 2000 to 2001 (to avoid results being primarily
related to imminent death); (6) had recorded laboratory values
consistent with laboratory error or event unrelated to primary
care (i.e., mean HbA1co4.0% or 18.0%, mean LDL-Co40.0
or 350.0mg/dL, mean SBPo100.0mmHg or 300.0, mean
DBPo50.0 or 200.0mmHg, BMIo10.0 or 100.0kg/m2);
or (7) pregnant during 2000.
In 2000, 215,946 cohort members received care in the VA.
There were 144,176 otherwise eligible patients with at least 1
intermediate outcome recorded and 80,207 patients with all 3
intermediate outcomes recorded.
Outcomes, Definitions of Simultaneous Control,
and Unit of Analysis
Data on intermediate outcomes were obtained from the Dia-
betes Registry. We calculated the mean of all HbA1c and LDL-C
results in 2000; for BP, we computed the mean of the last 3
available SBP and DBP results in 2000 (mean of all results if
o3). If a facility used total glycosylated hemoglobin, those
measurements were converted to HbA1c using the laboratory
equipment manufacturer’s conversion formula.
In 2000, VA recommendations were based on the 1997 VHA
Clinical Practice Guidelines for Diabetes Mellitus.33 Thus, si-
multaneous control was defined as having mean HbA1co9.0%,
LDL-Co130mg/dL, SBPo140mmHg, and DBPo90mmHg
in 2000. In addition, we conducted sensitivity analyses using
more stringent definitions of control based on the 2004
American Diabetes Association (ADA) Clinical Practice Re-
commendations34: mean HbA1co7.0%, LDL-Co100mg/dL,
SBPo130mmHg, and DBPo80mmHg. High-density lipopro-
tein cholesterol was not included in definitions because goals
were not part of the 1997 VHA diabetes guidelines.33
A patient was considered to have simultaneous control of
the intermediate outcomes for a given definition if all mean
measurements for HbA1c and LDL-C and last 3 measurements
of BP were all below the defined threshold during 2000.
Data Analysis
Except where stated otherwise, statistical analyses were con-
ducted using SASs version 9.1.35 We calculated the percent-
ages of cohort members who achieved simultaneous diabetes
control in 2000 using both of the above definitions.
To estimate the associations between having control of 1
intermediate outcome when having control of another, we cal-
culated the percent of patients with control of other interme-
diate outcomes (e.g., LDL-C, BP) when a given outcome (e.g.,
HbA1c) is and is not in control. This was done to represent
what might be seen among members of a clinic patient popu-
lation. Unadjusted associations were also examined by calcu-
lating unadjusted odds ratios (OR) between control of different
outcomes and Pearson correlations between intermediate out-
comes (results available from authors).
It is possible that there is an overestimate of simultaneous
control because patients without a record for a given outcome
may be less likely to have control. As a result, a sensitivity
analysis was conducted among all otherwise eligible patients
with at least 1 intermediate outcome recorded. In this analysis,
patients without all 3 intermediate outcomes were counted as
not having simultaneous control.
Separate logistic-regression models were fit using both VA
and ADA guidelines. The dependent variables were dichotomi-
zed (achieving control or not). For each model, ORs and Wald
confidence limits were calculated for the simultaneously ad-
justed relationship between control and (1) BMI (categorized
as: 10 to 24kg/m2 [referent category], 25 to 29, 30 to 34, 35 to
39 kg/m2, and 40 kg/m2) (2) race/ethnicity (white [referent
category], African American, American Indian, Asian, Hispan-
ic-black, Hispanic-white, and unknown race/ethnicity); (3)
gender; (4) age (categorized as: 18 to 49 [referent category],
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50 to 64, 65 to 79, and 80 years); (5) VA primary care visits
during 2000 (categorized as: 1 [referent category], 2 to 4, and
5); (6) individual variables indicating whether the patient
had a filled prescription at a VA pharmacy in 2000 for an oral
hypoglycemic agent, insulin, lipid-lowering agent (excluding
niacin), and niacin; and (7) the number of types of antihyper-
tensive medication for which the patients had a filled prescrip-
tion in 2000 (categorized as: none [referent category], 1, 2, and
3). For control of individual outcomes, ORs are also adjusted
for whether the patients met the control definitions for the
other individual outcomes. Risk-adjustment for comorbidities
was done using the Johns Hopkins ACG Case-Mix Systems.30
To determine the difference in expected levels of other
outcomes when 1 outcome is under control, separate simple
linear-regression models were fit for each definition of individ-
ual control. The dependent variable was the continuous value
for the outcome. Independent variables included control of the
other 2 outcomes. For example, the model for HbA1c using the
1997 VHA guideline definition included LDL-C o130mg/dL
and BP o140/90mmHg as independent variables. Other in-
dependent variables were identical to those in logistic-regres-
sion models.
Because patients are treated by individual primary care
programs (clusters), we performed all logistic and linear re-
gression models with the Huber-White estimate of variance36
(using Intercooled Statas version 8.237).
RESULTS
Analyses included 80,207 patients who met the inclusion/ex-
clusion criteria. These individuals were primary care patients
at 541 VA locations in 1999. Table 1 describes characteristics
of the patients.
The following percentages of the 144,176 otherwise eligi-
ble patients with at least 1 intermediate outcome reported did
not have records for the individual outcomes: HbA1c (19.3%),
LDL-C (38.5%), and BP (3.5%). Of 89,428 patients otherwise
eligible, 9.8% were excluded from the final analyses based on
requiring a record of a BMI.
Based on the VHA practice guidelines, 30.7% achieved
simultaneous control (Table 2). Percentages for control of in-
dividual outcomes were: HbA1c (81.5%), LDL-C (77.2%), and
BP (47.5%). Using the more stringent ADA guidelines, only
3.9% of patients achieved simultaneous control, and fewer pa-
tients achieved control for each individual outcome: HbA1c
(36.2%), LDL-C (40.7%), and BP (22.7%). Sensitivity analyses
counting patients without all 3 intermediate outcomes record-
ed as not having simultaneous control led to estimated rates of
simultaneous control of 17.3% of patients based on 1997 VHA
guidelines and 2.2% of patients based on 2004 ADA guide-
lines.
Patients with control of any 1 parameter of diabetes care
(i.e., HbA1c, LDL-C, BP) were only slightly more likely to have
control of other parameters. For example, 48% of patients with
LDL-C o130mg/dL had good BP control, compared with 44%
of patients with LDL-C 130mg/dL. The unadjusted associ-
ation between control of blood sugar and LDL-C was stronger
but still not tightly correlated; adequate glycemic control was
present in 83% of patients with LDL-C o130mg/dL, com-
pared with 75% of patients with LDL-C 130mg/dL. There
was a very small unadjusted inverse relationship between
glycemic control and BP control. Results were generally similar
using 2004 ADA definitions of risk factor control (Table 3).
The logistic-regression analysis for simultaneous control
using 1997 VA guidelines is presented in Table 4. The likeli-
hood of achieving simultaneous control was negatively asso-
ciated with: having a BMI 40kg/m2 compared with 18 to
24 kg/m2 (OR=0.66; 95% confidence interval [CI] 0.61 to
0.72); being African American (OR=0.65, 95% CI 0.61,
0.70), being Hispanic-black (OR=0.68, 95% CI 0.49, 0.93)
compared with white; being female (OR=0.76, 95% CI 0.68,
0.85); and taking 3 classes of antihypertensive agents com-
pared with taking no antihypertensive medications (OR=0.83,
95% CI 0.78, 0.88). In addition, simultaneous control was
positively associated with being American Indian compared
with white (OR=1.40, 95% CI 1.09, 1.81). Results for associ-
ations between control of vascular risk factors were similar to
those found in the unadjusted analysis. The association
between HbA1c control and LDL-C control was modest
(OR=1.51; 95% CI 1.44, 1.59); association between BP and
Table 1. Characteristics of Study Patients, n=80,207
Characteristic Mean (SD) or %
Mean hemoglobin A1c in 2000 (%) 7.70 (1.56)
Mean low density lipoprotein cholesterol in 2000
(mg/dL)
108.75 (30.87)
Mean systolic blood pressure in 2000 (mmHg) 141.16 (17.12)
Mean diastolic blood pressure in 2000 (mmHg) 74.87 (9.64)
Mean body mass index closest to the beginning
of fiscal year 2000 (kg/m2)
30.86 (5.87)
Body mass index categories (kg/m2)
24 10.66
25 to 29 34.94
30 to 34 31.87
35 to 39 14.68
40 7.85
Race/ethnicity







Mean age in 2000 65.10 (10.46)
Age in 2000
18 to 49 7.80
50 to 64 34.18
65 to 79 52.63
80 5.39
VA primary care visits during 2000
1 4.37
2 to 4 58.02
4 37.61
Pharmaceutical treatment-filled prescriptions
for blood sugar and cholesterol medicines in 2000
Oral hypoglycemic agent 59.17
Insulin 25.46
Lipid lowering agent (excluding niacin) 43.05
Niacin 1.03
Pharmaceutical treatment-number of classes of
antihypertensive medication for which there was a
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LDL-C control was even smaller (OR=1.26; 95% CI 1.21,
1.30), and there was essentially no association between BP
and HbA1c control (OR=0.95; 95% CI 0.92, 0.99). While fewer
patients achieved control of these outcomes using the more
stringent ADA definitions, the magnitudes of the associations
were similar (results available upon request from authors).
In order to provide a context for the associations between
control of individual outcomes, we performed linear regression
analysis with each clinical risk factor as a continuous variable
outcome (adjusting for all factors used in the logistic models).
For example, Table 5 displays the expected differences in LDL-
C, SBP, and DBP when 1 has control of HbA1c. Results show
only small-adjusted differences in each outcome between pa-
tients in and out of control of each of the other clinical param-
eters. For example, the difference between LDL-C for patients
with good control of HbA1c and those with poor control was
6.67mg/dL, favoring those with good HbA1c control. Other
differences were of even smaller magnitude.
DISCUSSION
In a health care system that has been shown to deliver superior
quality care and provide access to comprehensive primary care
services,13,38 simultaneous control of diabetes outcomes by
the standards of the era was achieved only by approximately
one-third of veterans. Furthermore, the associations between
control of individual risk factors are, for the most part, clini-
cally unimportant.3,5 Only the relationship between control of
HbA1c and LDL-C has slight clinical relevance.
Numerous medical, behavioral, and organizational inter-
ventions have been developed in recent years aimed at con-
trolling major cardiovascular risk factors among diabetic
patients.23,24 This is often done under the assumption that
there are underlying mechanisms that lead to overall lowering
of risk if there is focus on a limited set of these outcomes (e.g.,
HbA1c). For example, many believe patient characteristics (e.g.,
nonadherence) may lead to inadequate control of chronic ill-
nesses.39 This perspective implies that interventions address-
ing these characteristics (e.g., pill boxes) can simultaneously
improve multiple clinical outcomes. However, our results indi-
cate that there is little relationship between control of the prin-
cipal intermediate outcomes in diabetes. The present data
suggest that success with 1 outcome may not portend the same
benefits in other outcomes, even for the same disease.
Clinicians and researchers need to consider the potential
implications of this research. Clinicians may not wish to
aggressively pursue only 1 intermediate outcome under the
assumption that others will then be controlled. Also, interven-
tions may be faulty if they are based on an assumption that,
for example, a patient is simply ‘‘nonadherent’’ or ‘‘passive.’’
Rather researchers should explore adherence to or interest in
specific behaviors and treatments relating to particular man-
agement problems.40
Results from logistic-regression models for control of in-
dividual intermediate outcomes show a significant relation-
ship between BMI and all outcomes. Among variables included
in the analyses, the largest association with simultaneous
control reflects the well-documented relationship between





LDL-C Control o130 mg/dL
(% of Patients)
BP Control o140/90 mmHg
(% of Patients)
1997 Veterans Health Administration Definitions of Control of Intermediate Outcomes
When HbA1co9.0% 79.0 46.7
When HbA1c 9.0% 69.5 51.0
When LDL-Co130 mg/dL 83.4 48.4
When LDL-C130 mg/dL 75.3 44.4
When BPo140/90 mmHg 80.2 78.7





LDL-C Control o100 mg/dL
(% of Patients)
BP Control o130/80 mmHg
(% of Patients)
2004 American Diabetes Association Control Definitions of Intermediate Outcomes
When HbA1c o7.0% 43.8 22.5
When HbA1c 7.0% 39.0 22.8
When LDL-C o100 mg/dL 38.9 24.9
When LDL-C 100 mg/dL 34.3 21.2
When BP o130/80 mmHg 35.9 44.7
When BP 130/80 mmHg 36.2 39.5
Po.05= (for difference in proportions).
HbA1c, hemoglobin A1c; LDL-C, low-density lipoprotein cholestrol; BP, blood pressure.
Table 2. Control of Intermediate Diabetes Outcomes Among VA
Patients in Fiscal Year 2000, n=80,207
Intermediate Outcome Percent
1997 Veterans Health Administration Definitions of Control
of Intermediate Outcomes
Simultaneous control of all intermediate outcomes 30.7
Hemoglobin A1co9.0% 81.5
Low density lipoprotein cholesterolo130 mg/dL 77.2
Systolic blood pressureo140 mmHg and diastolic blood
pressureo90 mmHg
47.5
2004 American Diabetes Association Control Definitions of
Intermediate Outcomes
Simultaneous control of all intermediate outcomes 3.9
Hemoglobin A1co7.0% 36.2
Low density lipoprotein cholesterolo100 mg/dL 40.7
Systolic blood pressureo130 mmHg and diastolic blood
pressureo80 mmHg
22.7
The above definitions of simultaneous control are not mutually exclu-
sive.
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greater weight and higher BP.41 Weight was the strongest mod-
ifiable factor associated with control of vascular risks and may
be an appropriate focus for intervention by providers.
From the provider’s perspective, better outcomes appear to
be associated with simultaneously treating multiple risk fac-
tors, an indication of the aggressiveness of overall diabetes
treatment. As expected, more intensive treatment with medica-
tion is associated with having worse control of that outcome,
because providers are more likely to increase the intensity of
treatment when patients do not have control. However, our re-
Table 4. Predictors of Control of HbA1c, LDL-C, BP and All 3 Simultaneously, using 1997 Veterans Health Administration Definitions, n=80,207
Patient Characteristic HbA1c o9% OR
(95% CI)
LDL-C o130 mg/dL OR
(95% CI)




Body mass index (kg/m2)
18 to 24 Referent (N/A) Referent (N/A) Referent (N/A) Referent (N/A)
25 to 29 1.17 (1.10, 1.25) 0.93 (0.87, 0.99)  0.81 (0.76, 0.85)  0.89 (0.84, 0.94) 
30 to 34 1.14 (1.07, 1.22)  0.97 (0.91, 1.03) 0.69 (0.66, 0.73)  0.81 (0.77, 0.86) 
35 to 39 1.04 (0.97, 1.12) 0.98 (0.90, 1.06) 0.63 (0.59, 0.67)  0.74 (0.69, 0.80) 
40 1.10 (1.01, 1.20)  0.88 (0.81, 0.96)  0.54 (0.50, 0.57)  0.66 (0.61, 0.72) 
Race/ethnicity
White Referent (N/A) Referent (N/A) Referent (N/A) Referent (N/A)
African American 0.68 (0.63, 0.74)  0.66 (0.60, 0.72)  0.76 (0.71, 0.82)  0.65 (0.61, 0.70) 
American Indian 0.80 (0.60, 1.08) 1.22 (0.81, 1.84) 1.45 (1.11, 1.91)  1.40 (1.09, 1.81) 
Asian 0.65 (0.49, 0.87)  1.18 (0.86, 1.62) 1.18 (0.96, 1.45) 1.05 (0.81, 1.36)
Hispanic-black 0.56 (0.37, 0.85)  0.84 (0.62, 1.14) 1.03 (0.78, 1.37) 0.68 (0.49, 0.93) 
Hispanic-white 0.54 (0.39, 0.73)  1.07 (0.92, 1.25) 1.02 (0.92, 1.13) 0.87 (0.75, 1.01)
Unknown Race/ethnicity 0.96 (0.91, 1.02) 1.00 (0.93, 1.08) 0.90 (0.85, 0.94)  0.91 (0.87, 0.96) 
Gender (referent=male)
Female 1.12 (0.99, 1.26) 0.75 (0.67, 0.83)  0.82 (0.75, 0.90)  0.76 (0.68, 0.85) 
Age
18 to 49 Referent (N/A) Referent (N/A) Referent (N/A) Referent (N/A)
50 to 64 1.35 (1.27, 1.43)  1.19 (1.12, 1.27)  0.64 (0.60, 0.68)  0.95 (0.89, 1.01)
65 to 79 2.56 (2.38, 2.75)  1.54 (1.44, 1.65)  0.46 (0.43, 0.49)  0.95 (0.89, 1.01)
80 3.11 (2.77, 3.50)  1.54 (1.39, 1.71)  0.44 (0.40, 0.49)  0.98 (0.89, 1.07)
VA Primary care visits during FY2000
1 Referent (N/A) Referent (N/A) Referent (N/A) Referent (N/A)
2 to 4 1.13 (1.03, 1.24)  1.15 (1.06, 1.26)  1.00 (0.93, 1.08) 1.12 (1.03, 1.22) 
5 or more 0.93 (0.84, 1.03) 1.18 (1.07, 1.30)  0.94 (0.87, 1.02) 1.02 (0.93, 1.13)
Pharmaceutical treatment (referent=not having a filled prescription for drug category in FY2000)
Oral hypoglycemic agent 0.62 (0.58, 0.66) 0.99 (0.93, 1.04) 1.26 (1.20-1.33) 0.98 (0.94, 1.03)
Insulin 0.36 (0.34, 0.38) 1.01 (0.96, 1.06) 1.09 (1.05, 1.14) 0.74 (0.71, 0.78)
Lipid lowering agent (excluding niacin) 1.06 (1.01, 1.11) 0.79 (0.75, 0.84) 1.33 (1.29, 1.38) 1.19 (1.14, 1.23)
Niacin 1.45 (1.19, 1.76) 0.72 (0.62, 0.84) 1.21 (1.04, 1.41) 1.13 (0.96, 1.33)
Pharmaceutical treatment (number of types of antihypertension medication fills in FY2000)
None Referent (N/A) Referent (N/A) Referent (N/A) Referent (N/A)
1 1.47 (1.37, 1.57) 1.09 (1.01, 1.17) 0.76 (0.71, 0.81) 1.00 (0.94, 1.06)
2 1.69 (1.58, 1.80) 1.25 (1.15, 1.35) 0.56 (0.53, 0.60) 0.89 (0.84, 0.94)
3 or more 2.00 (1.87, 2.15) 1.57 (1.44, 1.70) 0.44 (0.42, 0.47) 0.83 (0.78, 0.88)
Control of intermediate outcomes
HbA1c o9% N/A 1.51 (1.44, 1.58) 0.95 (0.92, 0.99) N/A
LDL-C o130 mg/dL 1.51 (1.44, 1.59) N/A 1.26 (1.21, 1.30) N/A
SBP o140 mmHg and DBP o90 mmHg 0.96 (0.92, 0.99) 1.26 (1.21, 1.31) N/A N/A
Model intercept








Also adjusted for comorbidities using aggregated diagnostic groups, which is part of the Johns Hopkins Adjusted Clinical Groups Case-Mix Systems.
Po.05.
HbA1c, hemoglobin A1c; LDL-C, low-density lipoprotein cholestrol; BP, blood pressure; SE, standard error; SBP, systolic blood pressure; DBP, diastolic
blood pressure; FY, fiscal year; CI, confidence interval; OR, odds ratio.
Table 5. Adjusted Expected Difference in other Intermediate Diabetes Outcomes When a Specific Outcomes is Under Control, n=80,207
Control Definition Difference in HbA1c (%)
(95% CI)
Difference in LDL-C (mg/dL)
(95% CI)
Difference in SBP (mmHg)
(95% CI)
Difference in DBP (mmHg)
(95% CI)
1997 Veterans Health Administration Definitions of Control of Intermediate Outcomes
HbA1c o9.0% N/A 6.67 (7.33, 6.00) 0.47 (0.15, 0.79) 1.01 (1.19, 0.84)
LDL-C o130 mg/dL 0.29 (0.32, 0.25) N/A 2.38 (2.70, 2.05) 1.45 (1.63, 1.27)
BP o140/90 mmHg 0.01 (0.010, 0.037) 3.38 (3.91, 2.86) N/A N/A
The model also included other covariates used in the logistic regression model described in Table 4.
Po.05.
HbA1c, hemoglobin A1c; LDL-C, low-density lipoprotein cholestrol; BP, blood pressure; SE, standard error; SBP, systolic blood pressure; DBP, diastolic
blood pressure; FY, fiscal year; CI, confidence interval.
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sults indicate that provider vigilance in 1 outcome may be as-
sociated with better results for other outcomes, even in the face
of challenging biological disease. For example, more intensive
treatment for BP increased the likelihood of having control of
each intermediate outcome (e.g., the greater number of anti-
hypertensive medication types used, the greater the chance of
having HbA1c control). Rather than indicating a common un-
derlying biological mechanism, these results likely represent
the degree to which providers intensively treat patients with in-
termediate outcomes/risk factors that are out of control. The
opposite of higher level of vigilance, clinical inertia, has been
reported as a major issue in diabetes management.42–44
Demographic predictors of simultaneous control were
consistent with previous literature. Age was not predictive of
simultaneous control. Higher levels of hypertension were coun-
terbalanced by better lipid control observed among older pa-
tients. Both these phenomena are well-described.45,46 As in
other studies, African-American patients have worse control of
vascular risk factors than whites.12,47 Better simultaneous con-
trol in American Indians is predicted based on lower rates of
hypertension in this population.48,49 However, there were only,
234 American Indians in the study cohort. Finally, worse simul-
taneous control among women is likely because of the age dis-
tribution of cohort members reflecting the fact that VA patients,
both women and men, tend to be older than those in other
health care settings.50 Most women in the sample were probably
approaching or had reached menopause, and postmenopausal
women have higher BP and lipids than men of a similar age.45,46
This study has limitations and considerations. First, we
lack data on important confounders, especially lifestyle be-
haviors associated with our outcomes (e.g., physical activity,
diet, smoking status).41,51 Second, the study was conducted
among VA users, virtually all of whom are male and many have
complex chronic conditions. Finally, it is possible that our es-
timate of the rate of simultaneous control is high. Our calcu-
lation taking this possibility into account lead to estimates of
simultaneous control as low as 17.3% for the definition based
on the 1997 VHA guidelines and 2.2% for the more stringent
2004 ADA guidelines.
In summary, there is increasing recognition that control of
vascular risk factors for patients with diabetes is critical to re-
duce morbidity and mortality.1–6 Our results suggest that
health care providers cannot assume that successfully achiev-
ing therapeutic goals for 1 risk factor will be associated with
simultaneous control of other risk factors. Indeed, improving
the quality and outcomes of diabetes care may require the con-
sideration of individual characteristics when developing inno-
vative strategies. These findings do not negate the importance of
interventions that direct resources toward self-management
support, organizational structures and processes, or broad be-
havioral adaptations.52 Rather, our findings suggest the impor-
tance of addressing and monitoring individual outcomes when
attempting to achieve therapeutic goals for multiple outcomes
simultaneously. This may include both specific medical man-
agement and addressing psychosocial issues faced by patients
(e.g., readiness to change behaviors aimed at specific interme-
diate outcomes and social support for those changes).53
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